RxDoctor Payments Data

Oscar Grandas, MD

Vascular Surgery · Knoxville, TNNPI 1366550014

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (35.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 60.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $5,860 and has fallen 96.1% since, to $226 in 2025.

$8,548in general payments, 2019–2025

Across 62 payments — averaging $137.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Silk Road Medical, Inc.$2K
  • Bard Peripheral Vascular, Inc.$1K
  • Inari Medical, Inc.$352
  • Veloxis Pharmaceuticals, Inc.$125
  • Humacyte Global, Inc.$45
  • plus $153 from 6 others
$8,507in research payments, 2019–2025

Across 7 payments — averaging $1215.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Humacyte Global, Inc.$9K

What the payments were for

  • Consulting fees$2,60030%
  • Travel & lodging$3,02135%
  • Food & beverage$2,92734%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,548 in reported general payments places this provider in the 55th percentile of 117 vascular surgery providers in Tennessee.

See all vascular surgery providers in Tennessee

Medicare billing

Part B allowed, 2024
$140,737
Medicare patients
614
Services billed
1,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$38,479
Valganciclovir Hcl67$11,513
Cinacalcet Hcl39$9,947
Carvedilol ErCarvedilol Phosphate13$4,412
Cyclosporine ModifiedCyclosporine, Modified14$3,026
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$2,839
Famotidine286$2,451
Prednisone449$2,138
Tacrolimus59$1,746
Mycophenolate Mofetil39$1,473
Novolog FlexpenInsulin Aspart11$1,380
Rosuvastatin Calcium169$1,206
Bumetanide43$1,136
Amlodipine Besylate171$983
Potassium Chloride33$812

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →